SEC Form 4 · accession 0001209191-18-045652
Insys Therapeutics, Inc. · INSY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew G Long
Officer — Chief Financial Officer
Period of report
Aug 7, 2018
Accepted (ET)
Aug 7, 2018 · 3:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001516479
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 7, 2018 | A | 5,000 | $0.00 | A | 5,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Aug 7, 2018 | D | 5,000 | D | — | — | Common Stock | 5,000 | 10,000 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- F2on August 7, 2017, the Reporting Person received a restricted stock unit award ("RSUs"). The RSUs vest in 3 equal annual installments beginning on August 7, 2018 and will be fully vested on August 7, 2020, in all cases so long as there has been no break in the Reporting Person's continuous service through such date.